thus provides a good model to compare the transcriptome of all types of leukemias.
Introduction ___________________________________________________
To understand the mechanism of induction of leukemia in humans, the mouse has been considered to be an ideal model given the extent of genetic similarity between these two species. We have already shown that the Graffi murine leukemia virus (MuLV), when inoculated into newborn mice, induces a broad spectrum of leukemias of lymphoid (T or B) and non lymphoid (myeloid, erythroid or megakaryoblastic) origins. 1 We also demonstrated that the Graffi MuLV directly targets the c-myc, Fli-1, Pim-1 and Spi-1/PU.1 oncogenes 2 but also the Gris-1 locus that encodes an oncogenic truncated form of cyclin D2. 3, 4 We took advantage of the large spectrum of leukemias induced by the Graffi murine leukemia virus to analyze and compare the transcriptome of these leukemias with a DNA microarray approach. One clear advantage of microarray analysis is that genes that are not targeted through retroviral integration but act as oncogene upon deregulation can be equally identified. Using this approach, we recently identified several genes that are directly involved in erythroid and megakaryoblastic leukemias in both mouse and human. 5 In this report, we have specifically compared the transcriptomes of T and B lymphoid leukemias induced by Graffi MuLV to their corresponding controls. We identified new relevant signatures that highlight many potential markers or oncogenes for T and B leukemias (especially for pre-B-leukemia), some of which were common to both types of lymphoid leukemia. Among the selected genes, we validated the modulation of the expression of 10 genes out of 12, which functions remained poorly elucidated in lymphoid leukemias. Furthermore, for the first time, we provide data supporting a role for Fmn2, a member of the formin family in leukemogenesis in pre-B-ALL and particularly, in pediatric pre-B-ALL harboring the t(12;21) TEL/AML1 translocation.
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Materials and Methods

Human sample collection
For this study, samples from 12 pediatric pre-B-ALL were obtained from Dr. Daniel Sinnet (Sainte-Justine hospital, Montreal) while samples from 13 adult patients with different types of B leukemia were obtained from the Quebec Leukemia Cell Bank. As a control (CH), we pooled peripheral blood mononuclear cells isolated from ten healthy adults. Information relative to each patient is provided in supplemental Table S1. The research protocol was approved by Ethic Committees of all concerned institutions.
Mice sample collection
Newborn (≤ 24 Hrs) NFS mice were injected intraperitoneally with viral particles of Graffi MuLV variant GV-1. 4 (1. 10 6 PFU) or GV-1.2 (3. 10 6 PFU). 1 Lymph nodes, thymus, bone marrows and spleens were harvested from moribund mice for flow cytometry analysis and RNA extraction. All the experimental procedures were approved by the Animal Care Committee of Université du Québec à Montréal.
Flow cytometry and cell isolation
Flow cytometry was performed as previously described. 1 Cell populations (tumor or control) were purified from the hematopoietic organs by positive selection using magnetic beads coated with the chosen antibody. Leukemic cells were sorted as follow: T-cells from the thymus, B-cells from the enlarged lymph nodes, erythroid and megakaryoblastic cells For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From from the infiltrated spleen. Non leukemic control cells were sorted from a pool of 12 noninfected NFS mice: T-cells from the thymus, B-cells from the spleen, erythroblasts and megakaryoblasts from the bone marrow.
RNA isolation, Microarray hybridization and Data set normalization
Total RNA was directly isolated from spleen, thymus, lymph nodes, bone marrow samples or after cell-sorting with the Trizol reagent (Invitrogen, Burlington, ON, Canada) and 
Microarray data analyses
Using the gene expression profiles obtained from selected leukemias, the RMA values of the 45000 probsets were used to identify differentially expressed genes. Genes with signal intensity significantly higher (up-regulated), or lower (down-regulated) in leukemias versus control cells, i.e. with a 4 fold-change in expression levels were selected. To group microarrays and/or genes based on the high degree of their expression patterns, hierarchical clustering (complete linkage clustering, correlation uncentered) was constructed using GeneCluster software. 7 Probsets selected were further analyzed and the results were treated For personal use only. on September 14, 2017. by guest www.bloodjournal.org From with Tree View program. The NetAffx website (Affymetrix, Santa Clara, CA, USA) was also used to retrieve gene ontology (GO) annotations, probe sequences, and utilized as a link to Unigene (NCBI) for further functional studies. The microarray dataset was deposited at Gene Expression Omnibus under the accession number GSE12581.
Semi-quantitative RT-PCR
Reverse transcription reactions were performed with oligo(dT) as primer using the Omniscript enzyme (QIAGEN, Mississauga, Canada) and 100 ng of total RNA. Using a RT reaction corresponding to 10 ng of tumor RNA samples for each selected gene and to 2 ng for actin, the PCR reactions were performed with the Taq polymerase kit (Qiagen) and the following conditions: 94°C for 3 min, 94°C for 45 s, 56°C for 45 s, 72°C for 30 s with a final extension at 72°C for 10 min. Annealing temperature and number of cycles were optimized for each of the selected 12 genes with specific primers (Table S2 ) for semiquantitative analysis. PCR products were analyzed on agarose gel and band density was quantified with Quantity One Image Software, using the actin gene as an internal control.
Cellular localization of FMN2
NIH/3T3 fibroblasts, obtained from ATCC (Rockville MD), were grown in DMEM medium supplemented with 10% calf serum, 50U penicillin and 50 ug of streptomycin (Gibco, Invitrogen, Frederick, MD), 16h prior to transfection. Cells were respectively transfected with p-EGFP-N1 (control vector) and GFP-tagged Fmn2 using the polyfect reagent (Qiagen). FMN2 localization was analyzed by confocal microscopy 48h after transfection. For co-localization, cells were plated on glass coverslips, grown at 50%
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From confluency, and transfected as described above. Co-localization with the cell surface membrane was determined after cell staining for 5 min with 2.5 ug/ml of CellMask TM Plasma Membrane Stains (Invitrogen) and washing with PBS. Actin filament staining was performed after cell fixation for 20 min with 4% paraformaldehyde, followed by PBS washes and permeabilization for 5 min with 0.1% Triton X-100 in PBS. Cells were incubated 1h in PBS with 1% BSA, washed twice with PBS and the coverslips and then incubated with 0.3 uM of phalloïdin coupled to the Alexa Fluor 555 (Invitrogen) for 20 min.
After two washes with PBS, coverslips were mounted onto slides using Prolong Gold antifade reagent (Invitrogen) and observed within 24h by confocal microscopy. For alphatubulin staining, the primary antibody used was a mouse monoclonal anti-alpha-tubulin (1:
2000) (Sigma).
Colony formation in soft agar
To determine the anchorage-independent growth, colony formation was tested in soft agar as previously described. 8 Briefly, NIH/3T3 cells were transiently transfected with 2.5 ug of empty vector (pCMV), a Ras EJ 6.6 or pCMV-Fmn2 expression vector. After 48h, 1 x 10 4 cells were mixed with melted 0.3% agarose in DMEM medium and seeded in six-well plates on top of a 0.6% agarose base layer containing the same medium. The top layer was covered with 1.5 ml of DMEM. Cells were fed twice a week for 4 weeks and observed with an optical microscope (Ernst Leitz, 6MBH Wetzlar) at 40X. Colonies whose size was at least twice larger than that of control colonies were counted.
Results
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From To better elucidate the cancer signatures of B and T leukemias induced by the murine Graffi virus and to identify new oncogene candidates, a microarray analysis was performed on different types of B and T leukemias induced by this virus in comparison to non leukemic B (CB1 (CD45R + CD19 + )) and T (CT1 (CD4 + CD8 + )) cell populations. Three B leukemias (B1 and B2 (CD45R + CD19 + ), B3 (CD45R +low CD19 + Sca1 + )) and 3 T leukemias (T1 (CD4 + CD8 + ), T2 (CD4 -CD8 + ) and T3 (CD4 + CD8 -)) were chosen for the microarray experiments (NCBI GEO: GSE12581). We were especially interested to identify genes commonly deregulated in these tumors despite their heterogeneity and different stage of differentiation. Hierarchical clustering analyses of genes with a four fold-change in expression levels compared to control samples were used to obtain a general trend ( Figure   S1 ). This analysis allowed us to group leukemia samples (columns) and/or genes (rows) based on the similarity of their expression level. As a result, T leukemias and B leukemias were clustered separately, making 2 distinguishable groups ( Figure S1 ). According to these data, Graffi-induced T and B leukemias showed both distinct and common gene expression profiles. Indeed, clustering led to the formation of 6 subgroups representing probsets either specifically deregulated in B leukemias (188 overexpressed and 86 down-regulated), specifically deregulated in T leukemias (9 overexpressed and 48 down-regulated) or commonly deregulated in both types (8 overexpressed and 32 down-regulated). The complete list of genes presenting these lymphoid signatures is available at: www.biomed.uqam.ca/rassart/microarray2.html.
Gene expression profile specific for pre-B leukemias
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We first analyzed the expression profile of genes that could determine the stage of differentiation of the B leukemias. For all B leukemias, Rag2, Vpreb1, Igll1, Enpep, Ebf1, Il7R, Bst1 and Foxp1 were overexpressed compared to control cells (Table 1) . Results in this table correspond to the average expression calculated from all samples analyzed in the microarray analysis (B and T controls, B lymphoid, T lymphoid, myeloid, erythroid and megakaryoblastic tumors). Strong expression of these genes indicated that the three Graffi MuLV-induced B tumors were most likely at a pre-B differentiation stage. 5, [9] [10] [11] [12] [13] [14] [15] In all B leukemias, we also detected high levels of CD79a and CD79b mRNAs and low levels of CD20/Ms4a2 mRNA (Table 1) . A total of 274 probsets, corresponding to at least 218 genes, were found highly deregulated in all three B leukemias compared to control B lymphocytes.
Among these genes, 72 (86 probsets) were down-regulated and 146 (188 probsets) were upregulated ( Figure S1 ). Several of them had already been associated with B leukemias and are listed in Table 2 .
In order to identify new potential oncogenes associated with the development of pre-B leukemias, we further focused our analysis on 191 probsets (Table S3 ), mostly because they were not yet associated with lymphoid leukemias. Some of them (70 probsets including Crisp3 and Lphn2) were already involved in cancer but never associated with B leukemia.
Others (72 probsets) were never associated with cancer and 36 probsets had no assigned function. Finally, the 13 remaining probsets were involved in leukemias other than B leukemias (Table S3 ).
Gene expression profile specific for T leukemias
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From For all analyzed T leukemias, the expression levels of CD3, CD4 and CD8 markers, in comparison to the other tumor samples (B lymphoid, myeloid, erythroid and megakaryoblastic tumors), were in accordance with a T lineage immunophenotype (Table   1 ). Other markers known to be present at the T-cell surface were also detected (Table 1) .
Among these, Cd6 and Cd28 were the most specific to Graffi-induced T leukemias. We also observed that Cd160 was expressed in all 3 T leukemias but not in double positive control T-cells. Moreover, the two CD8 + tumors (T1 and T2) also expressed Cd7 and Dntt (TdT) ( Table 1) .
We found that 57 probsets corresponding to 48 genes showed the same pattern of deregulation in all three T leukemias in comparison to control T lymphocytes ( Figure S1 ; Table S3 ) but not in the B leukemias. Most of them (40 genes) were down-regulated while only 8 were up-regulated.
Nine probsets were already associated with T leukemias ( Table 2) , thus validating our approach. Among the remaining 48 probsets, 15 were associated with other cancers, 5
were related to leukemias other than T leukemias, 20 were neither associated with leukemias nor with other types of cancer and 8 had no assigned function (Table S3 ).
Expression profiles common to both B and T leukemias
The RMA analysis also revealed that 57 probsets (corresponding to 48 known genes) were modulated in both T and B leukemias compared to controls ( Figure S1 ). These genes may be associated with common characteristics of lymphoid leukemias or common oncogenic features and/or directly related to Graffi leukemogenesis.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Several genes already known to be associated with B and T leukemias were identified ( Table 2) . Moreover, among the 57 selected probsets, 36 had never been simultaneously associated to both types of lymphoid leukemias although some were already associated with one type (T leukemia: 10; B leukemia: 4; Table S3 ). Among the remaining probsets, 8 were identified in other cancers, 9 had never been associated with any types of cancer and 4 remain uncharacterized. Matr3 was the only gene already associated with leukemia (acute myeloid leukemia).
RT-PCR validation
To validate our microarray data, the expression levels of 12 genes specific to either B, T or to both leukemias (Fmm2, Arntl2, Bfsp2, Gfra2, Gmp6a, Gmp6b, Bmp7, Fbln1, Nln, Mettl1, Etv5 and Celsr1 (Tables 3 and S3 Figure 1A ; Tables 3 and S3 ). Gmp6a and Gmp6b, expected to be B leukemia-specific, showed significant overexpression in these tumors when compared to the control samples albeit in only 2 and 3 out of the 5 tested B leukemias, respectively. As expected, these two genes were not expressed in T leukemias or control samples. High expression levels of Bmp7 were significantly observed in all T leukemias while Fbln1 and Nln were overexpressed in 3 out of 5 T leukemias ( Figure 1B) . Mettl1, expected to be T leukemia-specific gene, was expressed in both T and B leukemias (including controls) ( Figure 1B) . For, Etv5, significant higher levels of expression were observed in 4 out of 5 B
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From leukemias and 3 out of 5 T leukemias ( Figure 1C ). Finally, Celsr1 was significantly overexpressed in most T leukemias compared to normal control (CT2) but, in contradiction with the microarray data, was poorly expressed in all B leukemias ( Figure 1C ). Similar validation results were obtained when using CD19 + splenic cells as normal control instead of CD45R + cells (not shown).
FMN2 induces anchorage-independent growth
We further focused our interest on Fmn2, a gene specifically overexpressed in B leukemias.
This gene is a member of the Formin family (FH proteins) and its product is highly conserved among the multidomain proteins involved in a growing range of actin-based processes. 16 Most importantly, they may promote cancer cells to become invasive and metastatic through their actin remodeling function. 17 We first studied the impact of Fmn2 over-expression on the anchorage-independent growth of NIH/3T3 cells, a classical assay to demonstrate the oncogenic potential of proteins. As shown in Figure 2 , the number of larger colonies formed in soft agar was significantly higher in Fmn2-expressing cells in comparison to control cells and similar in cells expressing the human Ras oncogene (Ras EJ 6.6) ( Figure 2 ). These results suggest that the FMN2 protein confers anchorage independence to NIH/3T3 cells.
FMN2 colocalizes with the plasma membrane and disrupts the actin network
We next determined the subcellular localization of FMN2. When GFP-tagged Fmn2 was transiently expressed in NIH/3T3, the protein was localized at the plasma membrane and within the cytoplasm ( Figure 3A ). This was further confirmed by co-localization of FMN2
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We also observed that NIH/3T3 cells expressing Fmn2 showed a reduced size and an abnormal morphology compared to control cells ( Figure 3 ). Moreover, Fmn2-expressing NIH/3T3 cells appeared rounded with long extensions ( Figure 3A-D) . Actin cytoskeleton is one of the cellular components that maintain cell shape and oncogenic transformation causes profound modifications linked to cell architecture. [18] [19] [20] Since the overexpression of Fmn2 in NIH/3T3 cells altered their morphology, we first tested the effect of its overexpression on actin filaments and on the microtubule network due to its reported action on actin cables. 21 As illustrated in figures 3C and D, cells overexpressing Fmn2 showed a drastic disruption of the actin and microtubule network and a reduced number of stress fibers compared to control cells.
Fmn2 gene overexpression in human pre-B leukemia
We measured the expression levels of human 9, 11, and 12) . Another tumor (lane 3) also showed high levels of Fmn2 expression suggesting that it could harbor the translocation as well although this remained to be confirmed.
Discussion
Graffi MuLV is a good model to gain new insights on leukemia development and progression and to identify new oncogenes. Gene expression profiling of each type of leukemia (T lymphoid, B lymphoid, myeloid, erythroid, megakaryoblastic) served to identify the cancer signatures of these specific leukemias. 5 In this paper, we determined the expression profile of 3 B and 3 T leukemias induced by this retrovirus in comparison to non leukemic cell controls (CB and CT) (Tables 2, 3 and S3) and to non lymphoid leukemias induced by the same virus ( Setting the minimal acceptable change in expression levels to four folds, we selected 388 probsets corresponding to 305 genes: 48 genes specifically modulated in T leukemias, 218 in B leukemias and 40 in both types in comparison to their respective controls.
Phenotypic properties and cancer signature of B leukemias
Our analysis suggests that B leukemias induced by Graffi MuLV are arrested at the pre-B stage of differentiation based on the high expression of pre-B specific markers (Table 1) . As in human pre-B-ALL, these leukemias overexpressed surface markers such as CD79a and CD79b and lacked CD20/Ms4a2 22 (Table 1 ). These results suggest that data retrieved from the gene profiling analysis of B leukemias should be especially relevant for human pre-B-ALL. Indeed, the results obtained for Fmn2 expression in human leukemias are in total agreement with the mouse data.
We selected 218 genes that were specifically deregulated in all 3 B leukemias and as presented in Table 2 , several of these genes were already known to be involved in lymphoid leukemia. This not only validates our microarray analysis but also further defines the cancer signature of these B lymphoid leukemias.
Phenotypic properties and cancer signature of T leukemia
Three distinct T leukemias (T1 (CD4 + CD8 + ), T2 (CD4 -CD8 + ), T3 (CD4 + CD8 -)) were chosen for the microarray experiments. These three different phenotypes are frequently observed in Graffi-induced T leukemias and are also representative of normal T cell types in healthy mice. 1 The retrovirus may have targeted slightly different T-cell blasts or transformed the targeted cells through these slightly different lineages. Based on the analysis, all T leukemias expressed markers specific for the T lineage (Table 1) as well as T-ALL associated markers such as Cd7 and Dntt (TdT). 23 However, we also found that all 3 T leukemias expressed high levels of Cd160. This marker, normally expressed on human NK and only on a subtype of human CD8 + cells, 24 seems to be overexpressed in almost all cases of B-cell chronic lymphocytic leukemia (CLL). 25 The analysis reveals that a total of 48 genes were strictly modulated in all T leukemias in comparison to control T-cells (Tables 2, 3 and S3), including 9 probsets already associated with leukemias. The overall data certainly reveals the existence of a common leukemic gene signature between T leukemias induced by the virus despite heterogeneity and phenotypic differences. We can speculate that similar deregulation patterns observed in these leukemias are associated with common characteristics of T leukemias or common oncogenic properties and are likely to be found in human T leukemias as well.
Cancer signature common to both B and T leukemias
Since we simultaneously analyzed gene expression profiles of B and T leukemias induced
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Among these, 23 probsets had already been associated with either T or B leukemias, with myeloid leukemia or other cancers (Table S3 ). These genes are certainly part of the common cancer signature of the T and B lymphoid leukemias and may be relevant for human lymphoid leukemias.
New potential markers and candidate oncogenes from B and T leukemias
The combination of our Graffi-induced tumor model and DNA microarrays allowed us to identify potential new markers of B and T leukemias that could also play an oncogenic role.
Among the selected 388 probsets (at least 305 genes), we further identified 275 genes not yet associated with lymphoid leukemias (Table S3 ). Some were specific to B, T leukemias or common to both types and 124 were obvious oncogene candidates since they had been already associated with non lymphoid leukemia or other cancers. More interestingly, we identified a total of 103 genes that had never been associated with any type of cancer and 32 probsets corresponding to uncharacterized genes or genes with unknown function.
By RT-PCR, we have validated changes in the expression levels of 10 out of the 12 genes selected according to their specificity for lymphoid leukemias (Figures 1 and S2 ). Our analysis revealed deregulation of the expression of several genes associated with Graffi MuLV-induced B leukemias (Table 1 ; Figures 1A and S2 ). These genes are Fmm2, Arntl2
(from the bHLH-PAS superfamily involved in regulating cell growth and differentiation 26 ), Gfra2 (from the glial cell line-derived neurotrophic factor receptor alpha family 28 and associated with primary neuroblastomas 29 and with some medullary thyroid carcinoma (MTC) tumor cells 30 ), Gmp6a and Gmp6b (members of the myelin proteolipid protein family and neuronal homologues of PLP/DM20 31 ).
We also identified several genes that were associated with T leukemias ( Figure 1B) , namely, Nln (from the metallopeptidase M3 family and involved in the metabolism of neurotensin 32 ), Bmp7 (a cytokine from the TGFβ superfamily and expressed in various types of cancer including prostate and breast cancers and melanoma [33] [34] [35] ) and Fbln1
(involved in heart development and in cell signalling involving growth factors 36 and associated with human neoplasia especially breast and ovarian cancers 37 ).
Etv5 (a member of the Ets family of transcription factors) was already described in association with B leukemias 38 but, according to our data, it appears also overexpressed in T leukemias ( Figure 1C) . In contrast, the modulation of expression of Celsr1 (involved in the regulation of cell polarity and in convergent extension 39 and expressed in gastrointestinal tumors 40 ), expected to be specific to both B and T leukemias based on the microarray analysis, was validated in all T leukemic samples ( Figures 1C and S2 ) but in only one B tumor ( Figure S2 ).
Finally, the high level of expression of Mettl1 (highly expressed in lung cancer 41 ) observed by the microarray analysis was not confirmed by RT-PCR (Tables 3 and S3 ; Figure 1B ) and, as for Celsr1, may reflect a certain degree of tumor heterogeneity as often observed in human leukemias as well.
We also compared gene expression between B tumors and normal B cells from the bone marrow sorted with an anti-CD45R antibody. This control includes B cells at different stages of maturation. The majority of the tested genes showed results similar to those obtained with spleen the B cells as control except for Fmn2, which was highly expressed in the bone marrow-derived cells (data not shown). Although this had not yet been reported, Fmn2 seems to be normally expressed at an early stage of B-cell lymphopoiesis in the bone marrow. Its expression decreases when B-cells move from the bone marrow to the spleen for maturation. This inverse correlation between the expression level of Fmn2 and B-cell maturation does not necessarily contradict its involvement in carcinogenesis. This is exemplified with GATA-2 which is essential for the maintenance and the proliferation of hematopoietic progenitors during normal hematopoiesis, 42 while having been implicated in tumorigenesis.
Overall, these results strongly suggest that the majority of the 275 selected probsets, in particular Fmn2, Arntl2, Gpm6a, Gpm6b, Bfsp2, Gfra2, Nln, Bmp7, Fbln1 and Etv5, are potentially new specific markers or oncogenes for B, T or B and T leukemias. Our analysis also identified several down-regulated genes such as KLK6 and TGFβI ( Table 2 ) that are already identified as tumors suppressors. Further studies are required to determine whether the modulation of expression also correlates with changes at the protein level and most importantly to determine their potential role in human leukemias. Regarding FMN2, our attempts to measure levels of this protein in mice tumors was hampered by the lack of specific antibodies.
Fmn2 gene is a good candidate oncogene
Among the 10 genes validated by RT-PCR, we further characterized Fmn2, which was specifically associated with B leukemias. Fmn2 is expressed in the developing and mature central nervous system 43 and in oocytes. 16 It was identified as a formin homology (FH) gene and the protein contains 2 characteristic FH protein domains: FH1 (proline-rich region) and FH2. The latter is responsible for actin nucleation. 44 The comparison of the mouse and human Fmn2 showed 74.7% sequence homology. Members of the formin family are implicated in cytokinesis, organogenesis and normal tissue homeostasis but are also involved in the invasive potential of cancerous cells and metastasis. 17 The implication of Fmn2 in the development of tumors had not yet been demonstrated even though human Fmn2 ESTs were found in several human tumors (parathyroid tumor, glioblastoma, retinoblastoma and chondrosarcoma). 17 In this paper, we report for the first time that Fmn2 is not only specifically overexpressed in B leukemias induced by the Graffi virus in mice (Figure 1 ; Tables 3 and   S3 ) but more importantly in human pre-B-ALL ( Figure 4 ).
Moreover, we demonstrate that ectopic expression of Fmn2 confers anchorageindependent growth to NIH3T3 cells ( Figure 2 ). This anchorage-independent growth conferred by FMN2 is probably related to its ability to induce the disruption of the actin and microtubules network and a reduction of the number of stress fibers. The biological role of 
Implication of Fmn2 in human pre-B-ALL
To determine the possible contribution of human Fmn2 to leukemogenesis, we measured its expression in 25 different B leukemia samples. We showed that this gene was specifically overexpressed in L1 and L2 pre-B-ALL (18/19 of cases) ( Figure 4 ) thereby agreeing with our microarrays data (Table 1) . More importantly, we show that four pediatric pre-B-ALL samples with a t(12;21) translocation produced the strongest signals. Such t(12;21) rearrangement involving the TEL/AML1 genes is more frequent in childhood-ALL (25-30%) with a B-precursor phenotype than in adult-ALL (3-5%). 48 Despite the fact that this translocation is associated with a favorable outcome and a good response to conventional chemotherapy, 25% of relapses occur off-therapy and require additional therapeutic strategies. The strong expression of Fmn2 in pediatric pre-B-ALL with the t(12;21) translocation suggests that the TEL/AML1 fusion protein could directly or indirectly upregulate Fmn2 gene expression. Together, these results suggest that very high For personal use only. on September 14, 2017. by guest www.bloodjournal.org From expression of Fmn2 in pre-B-ALL could be correlated with a t(12;21) translocation and could be used as marker although this has to be confirmed with a larger panel of samples.
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Cd7 -0,43 0,57 -3,54 -1,28 -1,35 -1,05 1,22 0,79 1,79 -2,32 -0,99 -2,26 -2,34 -2,03 -0,81 -1, 11 B leukemia probsets  1422122_at  0,21  0,06  0,43  -6,57 -6,89 -6,36  Fc receptor, IgE, low affinity II, alpha polypeptide  Fcer2a  1451713_a_at -0,05 -0,09 0,18  -6,26 -5,85 -5,85  Fc receptor, IgE, low affinity II, alpha polypeptide  Fcer2a  1438030_at  -0,28 -0,01 0,06  -5,23 -4,94 -4,27  RAS, guanyl releasing protein 3  Rasgrp3  1447998_at  0, B leukemia probsets  1450063_at -0,33 -0,20 -0,19 2,59 3,05 3,01  formin 2  Fmn2  1429688_at -0,48 -0,13 -0,38 3,24 2,78 2,75  aryl hydrocarbon receptor nuclear translocator-like 2  Arntl2  1434463_at -0,45 -0,48 -0,29 2,98 3,36 3,39  beaded filament structural protein 2, phakinin  Bfsp2  1423007_a_at -0,41 -0,04 -0,01 3,12 3,22 2,68 glial cell line derived neurotrophic factor family receptor Gfra2 1426442_at -0,06 -0,04 0,09 3,15 2,79 2,42 glycoprotein m6a Gpm6a 1425942_a_at -0,43 -0,54 -0,09 6,93 6, 35 2,55 glycoprotein m6b Gpm6b T leukemia probsets 1419122_at 2,33 2,16 2,85 -0,41 -0,07 -0,15 methyltransferase-like 1 Mettl1 1451555_at 2,32 3,23 2,07 -0,06 0,07 0,09 neurolysin (metallopeptidase M3 family) Nln 1432410_a_at 3,09 1,56 3,28 -0,36 -0,15 -0, 19 bone morphogenetic protein 7 Bmp7 1451119_a_at 2,75 2,25 1,58 -0,12 -0,28 -0, 27 fibulin 1 Fbln1 B and T leukemia commun probsets (25) . RT-PCRs were performed in triplicate for each gene.
The actin gene was used as an internal control as described in Materials and Methods and expression level in each leukemia is presented as a selected gene/actin density ratio.
Statistical analysis was performed using One-way ANOVA and p <0.05 was considered to be significant (* p<0.05, ** p<0.01, *** p<0.001) compared to the respective control (CH).
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